KR20150043465A - 화학 공정 - Google Patents

화학 공정 Download PDF

Info

Publication number
KR20150043465A
KR20150043465A KR20157006531A KR20157006531A KR20150043465A KR 20150043465 A KR20150043465 A KR 20150043465A KR 20157006531 A KR20157006531 A KR 20157006531A KR 20157006531 A KR20157006531 A KR 20157006531A KR 20150043465 A KR20150043465 A KR 20150043465A
Authority
KR
South Korea
Prior art keywords
formula
compound
solvent
chloride
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157006531A
Other languages
English (en)
Korean (ko)
Inventor
프랭크 호스너
존 브라이스 스트라찬
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20150043465A publication Critical patent/KR20150043465A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR20157006531A 2012-08-15 2013-08-14 화학 공정 Ceased KR20150043465A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683369P 2012-08-15 2012-08-15
US61/683,369 2012-08-15
PCT/EP2013/067035 WO2014027045A1 (en) 2012-08-15 2013-08-14 Chemical process

Publications (1)

Publication Number Publication Date
KR20150043465A true KR20150043465A (ko) 2015-04-22

Family

ID=49080842

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157006531A Ceased KR20150043465A (ko) 2012-08-15 2013-08-14 화학 공정

Country Status (12)

Country Link
US (2) US9273001B2 (https=)
EP (2) EP3401316B1 (https=)
JP (2) JP6389174B2 (https=)
KR (1) KR20150043465A (https=)
CN (2) CN107163038B (https=)
AU (3) AU2013304102B2 (https=)
BR (1) BR112015003101B1 (https=)
CA (1) CA2881935A1 (https=)
ES (2) ES2678697T3 (https=)
IN (1) IN2015KN00323A (https=)
RU (1) RU2644160C2 (https=)
WO (1) WO2014027045A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6758196B2 (ja) 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｃｏｐｄの治療におけるフルチカゾンフランカルボン酸エステル
US10023535B2 (en) 2014-11-03 2018-07-17 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
CN108069956B (zh) * 2016-11-18 2021-03-16 扬州奥锐特药业有限公司 1-氮杂双环[2,2,2]辛-4-基苯基酮化合物及其制备方法和应用
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
CN107935917A (zh) * 2017-10-30 2018-04-20 广东莱佛士制药技术有限公司 一种1‑(2‑氯乙基)‑4‑哌啶甲酸酯的合成方法
CN109956938A (zh) * 2017-12-26 2019-07-02 天津金耀集团有限公司 乌美溴铵中间体晶型及其制备方法和以该中间体制备乌美溴铵的方法
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
PT115583B (pt) * 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate
CN117310022B (zh) * 2023-09-22 2024-05-17 山东泰合医药科技有限公司 一种分离和检测乌美溴铵中间体奎宁环二苯甲醇有关物质的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998832A (en) * 1975-04-16 1976-12-21 G. D. Searle & Co. Anti-diarrheal compounds
US4540780A (en) * 1983-06-02 1985-09-10 Warner-Lambert Company Diphenylmethylene piperidines
FR2816618B1 (fr) * 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
PE20060259A1 (es) * 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
JP4841279B2 (ja) * 2006-03-23 2011-12-21 一般財団法人 化学物質評価研究機構 被検物質の発がん性予測方法
WO2011029896A1 (en) * 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드

Also Published As

Publication number Publication date
CN104619706A (zh) 2015-05-13
IN2015KN00323A (https=) 2015-07-10
JP6799037B2 (ja) 2020-12-09
US20160159786A1 (en) 2016-06-09
US9273001B2 (en) 2016-03-01
CA2881935A1 (en) 2014-02-20
JP2015524832A (ja) 2015-08-27
WO2014027045A1 (en) 2014-02-20
EP3401316B1 (en) 2021-08-04
JP6389174B2 (ja) 2018-09-12
BR112015003101A2 (pt) 2017-07-04
EP2885298A1 (en) 2015-06-24
EP3401316A1 (en) 2018-11-14
CN107163038A (zh) 2017-09-15
AU2016213768B2 (en) 2018-01-04
EP2885298B1 (en) 2018-06-13
ES2678697T3 (es) 2018-08-16
ES2893473T3 (es) 2022-02-09
AU2013304102B2 (en) 2016-09-01
CN107163038B (zh) 2020-07-28
US9657011B2 (en) 2017-05-23
BR112015003101B1 (pt) 2022-06-14
RU2015104269A (ru) 2016-10-10
AU2013304102A1 (en) 2015-02-26
AU2016262787A1 (en) 2016-12-15
RU2644160C2 (ru) 2018-02-08
US20150232423A1 (en) 2015-08-20
CN104619706B (zh) 2017-06-20
AU2016213768A1 (en) 2016-09-01
JP2018203752A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
JP6799037B2 (ja) 化学的方法
JP2014516072A (ja) アピキサバン製造方法
EP3988545A1 (en) Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof
JP2013527239A (ja) イクサベピロンの固体形
JP7535367B1 (ja) ビナフチル骨格を有するジエステル化合物の結晶及びその製造方法
JP2015521635A (ja) ソリフェナシン又はその塩の調製方法
US11286254B2 (en) Process for the synthesis of 2-benzhydryl-3 quinuclidinone
US6433173B1 (en) Process for the preparation of ipidacrine or ipidacrine hydrochloride hydrate
JP4238978B2 (ja) ベンゾアゼピン化合物及びその製造法
JP5250693B2 (ja) カルボン酸化合物の製造方法
WO2025046257A1 (en) A substantially pure propentofylline and preparation thereof
KR20240135640A (ko) 뉴로키닌-1 길항제 전구약물 화합물의 결정형
KR900002054B1 (ko) 퀴놀론 유도체의 제조방법
WO2013114232A1 (en) Process for preparation of crystalline form l of ilaprazole
WO2005061478A1 (ja) ４−アルコキシカルボニルテトラヒドロピラン又はテトラヒドロピラニルー４−カルボン酸の製法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180719

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190819

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190819

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I